# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Higuchi Ichiyō (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI029-SYN-TD
- Date: 1896-04-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Aiko Lindgren-Tanaka, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Results visit: sputum tests, with infectious diseases consultation the same day. **S**

## History of present illness

Ms. Higuchi returns three days after her first visit for her results and is seen by Dr. Abernathy-Okoye of infectious diseases today. She brought the second and third sputum specimens, the last collected on waking this morning. Since her first visit she has stayed home, slept in her own room with the window open, and worn a surgical mask in the shared rooms; no one has visited. The cough is unchanged, with a little white sputum and no blood, and she still has evening fevers and night sweats. She is eating a little more since the dietitian's first call. She has not written since her first visit. She is worried about the people she lives with and about the cost of treatment. **S**

| Element | Detail |
|---|---|
| Symptoms | Cough, evening fevers and night sweats unchanged; no hemoptysis |
| Precautions | At home with a mask in shared rooms; no visitors |
| Testing | Three sputum specimens complete; blood results back |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Cough with a little white sputum; no blood; breathless on the stairs |
| Constitutional | Positive | Evening fevers, night sweats and tiredness |
| Eyes | Negative | No blurred vision |
| Psychiatric | Positive | Worried about her household and costs; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Isoniazid 100 mg tablets, two tablets (200 mg) daily **S**
- Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily **S**
- Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily **S**
- Ethambutol 100 mg tablets, six tablets (600 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 96/60 mmHg; pulse 100 bpm; respirations 20/min; temperature 37.6 °C; oxygen saturation 96% on room air; weight 38.4 kg; BMI 17.5 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Thin and tired; weight 38.4 kg; temperature 37.6 °C, pulse 100; seen in an airborne infection isolation room with staff wearing respirators |
| Respiratory | Fine crackles over the right upper zone; no wheeze |
| Eyes | No icterus |
| Abdomen | Soft and non-tender; liver not enlarged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pulmonary tuberculosis, smear-negative, Xpert-confirmed** (A15.0). All three sputum smears are negative for acid-fast bacilli, but Xpert MTB/RIF Ultra on the first specimen detected Mycobacterium tuberculosis at a low level with no rifampin resistance, which with her symptoms and the right upper lobe opacities confirms pulmonary tuberculosis. Cultures and susceptibility testing are pending. HIV, hepatitis B surface antigen, hepatitis C antibody and the pregnancy test are negative. Liver and kidney tests are normal, hemoglobin A1c 5.1%, and visual acuity 85 letters in each eye with normal color vision. At 38.5 kg she is below the 40 kg needed for the four-month rifapentine-moxifloxacin regimen, so the standard six-month regimen is used. Dr. Abernathy-Okoye agrees the regimen, doses and monitoring. **S**
   - Isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg and ethambutol 600 mg daily, with pyridoxine 50 mg, from today; first dose taken in the clinic.
   - Daily video-observed therapy with the public health center from tomorrow.
   - Notification to the public health center today.
   - Liver tests and vision at two weeks; call the same day for nausea, vomiting, abdominal pain, yellow eyes, dark urine or any change in vision.
   - Expect orange urine and tears.
2. **Moderate protein-calorie malnutrition** (E44.0). Weight 38.4 kg; eating slightly more. **S**
   - Second dietitian visit next week; supplement drinks twice daily.
3. **Low income** (Z59.6). Treatment costs are her main fear. Outpatient tuberculosis drugs, X-rays and sputum tests qualify for public funding of 95 percent under the Infectious Diseases Control Law. **S**
   - Medical social worker to complete the public funding application with her today.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Sputum smear and culture | At diagnosis, at two weeks, and at the end of the intensive phase (two months) | Completed today | Three specimens, one on waking: smears negative for acid-fast bacilli; liquid and solid cultures pending |
| Laboratory | Xpert MTB/RIF Ultra (nucleic acid amplification with rifampin resistance) | At diagnosis | Completed today | Mycobacterium tuberculosis detected, low; rifampin resistance not detected |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Ordered | Phenotypic susceptibility to first-line drugs to be set up on the first positive culture |
| Laboratory | HIV test | At diagnosis | Up to date | HIV-1/2 antigen and antibody test negative |
| Laboratory | Hepatitis B and C serology | At diagnosis | Up to date | Hepatitis B surface antigen, surface antibody and core antibody negative (not immune); hepatitis C antibody negative |
| Laboratory | Pregnancy test | Before starting treatment in a woman who could be pregnant | Up to date | Negative at intake |
| Laboratory | Diabetes screen (hemoglobin A1c) | At diagnosis | Up to date | 5.1% at intake |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms | Up to date | Normal at intake (ALT 12, AST 19 U/L, bilirubin 0.4 mg/dL); albumin 3.3 g/dL |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Up to date | 85 letters in each eye with normal color vision at intake, before ethambutol |
| Imaging | Chest X-ray | At diagnosis and at the end of treatment as a new baseline | Up to date | Right upper lobe opacities without a cavity at intake |
| Medication safety | Regimen choice and weight-based doses | At the start of treatment | Completed today | Standard six-month regimen; not eligible for the four-month rifapentine-moxifloxacin regimen at 38.5 kg. Isoniazid 5, rifampin 12, pyrazinamide 26 and ethambutol 16 mg/kg |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | First dose observed in the clinic; video-observed therapy from tomorrow |
| Medication safety | Rifampin drug-interaction review, including hormonal contraception | With every new medicine | Completed today | No other medicines; told that rifampin weakens hormonal contraceptives and interacts with many drugs |
| Self-management | Home precautions and the criteria for release | Until two weeks of treatment with clinical improvement, for smear-negative disease | Completed today | Precautions at home continue; smear-negative, so treated as an outpatient |
| Referral | Notification to the public health center (Infectious Diseases Control Law, Article 12) | At once on diagnosis | Completed today | Notified today; the center was told of the suspected case at intake |
| Referral | Contact investigation (household and close contacts) | Led by the public health center, from diagnosis | Referred | The public health center will assess her household and close contacts; their results belong to their own records |
| Referral | Public funding and other help with costs | At diagnosis | Completed today | Public funding application completed with the social worker |
| Self-management | Weight and nutrition | Every visit; dose review if weight changes by more than about 5 kg | Completed today | 38.4 kg; dietitian and supplement drinks |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Up to date | PHQ-9 8 at intake, item 9 scored 0 |
| Referral | Infectious diseases consultation | Once at diagnosis, then as advised | Completed today | Seen today by Dr. Abernathy-Okoye |

## Goal progress

- Complete 182 daily doses within about six and a half months by video-observed therapy. In progress; target 1896-10-20. **S**
- Sputum culture negative at two months. In progress; target 1896-10-20. **S**
- Weight at least 44 kg (BMI about 20) by the end of treatment. In progress; target 1896-10-20. **S**
- Keep writing on a paced schedule without losing income during treatment. In progress; target 1896-10-20. **S**
- No drug-induced liver injury or loss of vision during treatment. In progress; target 1896-10-20. **S**

## Medication changes

- Started: Isoniazid 100 mg tablets, two tablets (200 mg) daily **S**
- Started: Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily **S**
- Started: Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily **S**
- Started: Ethambutol 100 mg tablets, six tablets (600 mg) daily **S**
- Started: Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases 2016;63(7):e147-e195)
- Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025), American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America (American Journal of Respiratory and Critical Care Medicine 2025;211(1):15-33)
- WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022), World Health Organization
- Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017), American Thoracic Society, Infectious Diseases Society of America, and Centers for Disease Control and Prevention (Clinical Infectious Diseases)
- Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current), Ministry of Health, Labour and Welfare, Japan
- 結核医療費の公費負担 (Public funding of tuberculosis medical costs under Articles 37 and 37-2 of the Infectious Diseases Control Law) (current), Niigata Prefecture, Japan
- Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012), Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)

## Follow-up

- Two-week review with liver tests, vision and a sputum specimen. Call the same day for hepatitis symptoms or any change in vision. **S**
- Next scheduled visit 1896-05-01: two-week review on treatment: culture result, liver tests, vision, and release from precautions. **S**
